Adrian Quartel

Bio:

Dr. Quartel is the Chief Medical Officer at Zevra Therapeutics, responsible for the overall direction of clinical development and medical and regulatory affairs. During his time Zevra he led the team to the successful marketing application of MIPLYFFA® for the treatment of Niemann Pick disorder type C. Prior to joining Zevra he was the Chief Medical Officer of Acer Therapeutics, where he played a key role in guiding clinical development, medical affairs and regulatory compliance where he led the successful regulatory submission of OLPRUVA® for the treatment of Urea Cycle Disorders. Prior to that, he was the Chief Medical Officer at Adamas Pharmaceuticals, a company focused on drug development for neurological diseases,. He previously served as the former Group Vice President of Global Medical Affairs at BioMarin Pharmaceuticals Inc., where he spearheaded the launch of six treatments for rare diseases or genetic disorders, including KUVAN®, VIMIZIM®, and Brineura®. Before his tenure at BioMarin, he oversaw clinical development and held senior medical leadership positions at Astellas, Chiltern, and ICON Clinical Research. Earlier in his career, Dr. Quartel worked as a clinical research fellow at UCLA Cedar Sinai and as a resident in cardio-thoracic surgery at Erasmus University Medical Center. He holds an M.D. from Erasmus University Medical School, Rotterdam, and has a postgraduate specialization in pharmaceutical medicine from the Faculty of Pharmaceutical Medicine in London. Dr. Quartel is board certified by the General Medical Council (GMC) in pharmaceutical medicine in the United Kingdom.